Literature DB >> 26189998

Urgent surgery for intraperitoneal bleeding from GIST during imatinib therapy.

Takehiko Enomoto1, Tatsuo Kanda2, Kazuhito Yajima1, Seiichi Hirota3, Atsushi Matsuki1, Shin-Ichi Kosugi1, Takashi Kato4, Yoichi Ajioka4, Katsuyoshi Hatakeyama1.   

Abstract

The rupture or bleeding of a gastrointestinal stromal tumor (GIST) is a life-threatening adverse event that can happen during imatinib therapy, but few such cases have been reported in the medical literature. Here, we report a case of intraperitoneal bleeding from GIST during imatinib therapy. A 75-year-old man was diagnosed with a large GIST with liver metastasis and admitted to our hospital for abdominal pain on the 13th day of imatinib therapy. The pain disappeared after 7 days of hospitalization; however, the patient complained of diffuse abdominal pain 5 days after discharge. He presented with muscular guarding, and abdominal-pelvic CT demonstrated dense ascites. The tentative diagnosis was peritoneal hemorrhage from GIST, and urgent laparotomy was performed. During the laparotomy, we noted hemoperitoneum of approximately 500 ml; we resected a bulky metastatic tumor on the greater omentum and a primary tumor on the jejunum. The patient took imatinib (400 mg daily) from the ninth postoperative day and underwent monthly checkups for 9 months after the surgery. When GIST patients complain of sudden and severe abdominal pain during imatinib therapy, bleeding from GIST should be considered as a possible adverse effect of imatinib.

Entities:  

Keywords:  Gastrointestinal stromal tumor; Imatinib mesylate; Rupture; Surgery

Year:  2010        PMID: 26189998     DOI: 10.1007/s12328-010-0143-3

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  15 in total

1.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Authors:  Maria Debiec-Rychter; Raf Sciot; Axel Le Cesne; Marcus Schlemmer; Peter Hohenberger; Allan T van Oosterom; Jean-Yves Blay; Serge Leyvraz; Michel Stul; Paolo G Casali; John Zalcberg; Jaap Verweij; Martine Van Glabbeke; Anne Hagemeijer; Ian Judson
Journal:  Eur J Cancer       Date:  2006-04-18       Impact factor: 9.162

2.  Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.

Authors:  Chun-Nan Yeh; Tsung-Wen Chen; Feng-Yuan Liu; Yi-Yin Jan; Miin-Fu Chen
Journal:  Langenbecks Arch Surg       Date:  2006-10-06       Impact factor: 3.445

Review 3.  [Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate].

Authors:  Akira Yokoyama; Naohiro Dairaku; Masao Kusano; Shinsuke Koshita; Norihiro Shimada; Tetsuya Yamagiwa; Yasuhiro Kojima; Toshiaki Ojima; Shinichi Ikeya; Haruo Nakayama; Yoshiki Sugai; Nobuo Hiwatashi; Shigeyuki Asano
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  2008-11

4.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

5.  A ruptured large extraluminal ileal gastrointestinal stromal tumor causing hemoperitoneum.

Authors:  Shoji Hirasaki; Kohei Fujita; Minoru Matsubara; Hiromitsu Kanzaki; Hiromichi Yamane; Masato Okuda; Seiyuu Suzuki; Atsuko Shirakawa; Hideyuki Saeki
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

Review 6.  Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Pol J Pathol       Date:  2003       Impact factor: 1.072

7.  Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread.

Authors:  Guy J C Burkill; Mohammed Badran; Omar Al-Muderis; J Meirion Thomas; Ian R Judson; Cyril Fisher; Eleanor C Moskovic
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

Review 8.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Authors:  George D Demetri; Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Paolo Casali; Haesun Choi; Christopher L Corless; Maria Debiec-Rychter; Ronald P DeMatteo; David S Ettinger; George A Fisher; Christopher D M Fletcher; Alessandro Gronchi; Peter Hohenberger; Miranda Hughes; Heikki Joensuu; Ian Judson; Axel Le Cesne; Robert G Maki; Michael Morse; Alberto S Pappo; Peter W T Pisters; Chandrajit P Raut; Peter Reichardt; Douglas S Tyler; Annick D Van den Abbeele; Margaret von Mehren; Jeffrey D Wayne; John Zalcberg
Journal:  J Natl Compr Canc Netw       Date:  2007-07       Impact factor: 11.908

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.